Prosight Management’s AbCellera Biologics ABCL Stock Holding History

Prosight Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,815,652	Closed	-$6.28M	–	40
2025 Q1	$6.28M	Sell	2,815,652 -4,534,348	-62%	-$13M	2.06%	20
2024 Q4	$21.5M	Sell	7,350,000 -1,729,539	-19%	-$4.82M	5.95%	5
2024 Q3	$23.6M	Buy	9,079,539 +6,726,906	+286%	+$18.6M	5.81%	4
2024 Q2	$6.96M	Buy	2,352,633 +562,633	+31%	+$2.13M	2.08%	16
2024 Q1	$8.11M	Buy	1,790,000 +90,000	+5%	+$459K	2.26%	14
2023 Q4	$9.71M	Sell	1,700,000 -746,000	-30%	-$3.46M	3.9%	9
2023 Q3	$11.3M	Sell	2,446,000 -104,000	-4%	-$633K	3.57%	9
2023 Q2	$16.5M	Buy	2,550,000 +1,796,472	+238%	+$12.3M	4.82%	8
2023 Q1	$5.68M	Buy	753,528 +430,774	+133%	+$3.91M	2.69%	16
2022 Q4	$3.27M	Buy	322,754 +236,250	+273%	+$2.73M	1.78%	19
2022 Q3	$856K	Buy	+86,504	New	+$949K	0.46%	35

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Prosight Management's ABCL Position: Q2 2025 in Review

Prosight Management sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 2,815,652 shares — an estimated $6.28M sold.

Prosight Management first reported a position in ABCL in Q3 2022 and held it in 11 quarters. The position peaked at $23.6M in Q3 2024. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

Prosight Management reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
Prosight Management sold 2,815,652 AbCellera Biologics shares in Q2 2025, an estimated $6.28M.
Prosight Management first reported a position in AbCellera Biologics in Q3 2022 and held it in 11 quarters.
Prosight Management's AbCellera Biologics position peaked at $23.6M in Q3 2024.
128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on Prosight Management's 13F filing for Q2 2025, filed 14 Aug 2025.